This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Anacor Pharmaceuticals Reports Third Quarter 2013 Financial Results

Corporate

On October 27, 2013 we entered into a settlement agreement with Valeant Pharmaceuticals International, Inc. (Valeant) in which Valeant agreed to pay us $142.5 million to settle all existing and future claims, including the recent arbitration with Valeant related to Dow Pharmaceutical Sciences (DPS), our dispute with Medicis Pharmaceutical Corporation and all other disputes between Anacor, Valeant and DPS related to Anacor’s intellectual property, confidential information and contractual rights. We received the payment on November 7, 2013.

Selected Third Quarter 2013 Financial Results

Revenues for the quarter ended September 30, 2013 were $3.6 million, compared to $2.5 million for the comparable period in 2012. The increase was due to revenue recognized for research services performed under the Gates Foundation agreement in the third quarter of 2013, partially offset by declines in revenues for research work performed under other research and development agreements, including our agreements with not-for-profit organizations for neglected diseases and with Medicis.

Research and development expenses were $12.5 million for the third quarter of 2013, compared to $13.6 million for the same quarter in 2012. Research and development expenses decreased from the same quarter in 2012 primarily due to a decrease in expenses for the tavaborole program, partially offset by an increase in expenses related to our AN2728 program and our new research agreement with the Gates Foundation.

General and administrative expenses for the third quarter of 2013 were $6.8 million, compared to $2.8 million for the comparable period in 2012. The increase in general and administrative expenses in the third quarter of 2013 compared to the same period in 2012 was primarily due to an increase in legal fees from our legal proceedings related to our disputes with Valeant and Medicis, as well as market research activities for tavaborole.

Cash, cash equivalents, short-term investments and restricted investments totaled $39.3 million, including restricted investments of $4.7 million, at September 30, 2013.

Financial Outlook

We anticipate ending 2013 with at least $160.0 million in cash, cash equivalents, short-term investments, and restricted investments, including the Valeant arbitration settlement proceeds of $142.5 million. We believe that these capital resources will be sufficient to meet our anticipated operating requirements for at least the next twelve months.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,073.60 -6.54 -0.04%
S&P 500 2,118.33 +0.64 0.03%
NASDAQ 5,084.9490 -7.1360 -0.14%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs